

Appl. No. 10/507,046

Amdt. Dated January 3, 2007

Reply to Office Action of October 3, 2006

### Amendments to the Claims

This listing of claims will replace all prior version and listings of claims in the application:

### Listing of Claims:

1. (Currently amended): An isolated ~~[[A]]~~ anti-anti-idiotypic antibody, characterized in that it
  - (i) reacts with an anti-idiotypic antibody which represents an internal image of the antigen CA125,
  - (ii) is specific for the tumour-associated antigen CA125 and reacts with this antigen, and
  - (iii) mediates an antibody-dependent cellular cytotoxicity against CA125-expressing tumour cells.
2. (Currently amended): The isolated ~~[[A]]~~ anti-anti-idiotypic antibody as claimed in claim 1, characterized in that it reacts with the monoclonal anti-idiotypic antibody ACA125 produced by the hybridoma 3D5~~[[ ( ) ]]~~, which is deposited under DSM ACC2120~~[[ ( ) ]]~~.
3. (Currently amended): The isolated ~~[[A]]~~ anti-anti-idiotypic antibody as claimed in claim 1 or claim 2, characterized in that it is produced as a result of a polyclonal immune response by vaccination with an anti-idiotypic antibody which represents an internal image of the antigen CA125.
4. (Currently amended): The isolated ~~[[A]]~~ anti-anti-idiotypic antibody as claimed in claim 1 or claim 2, characterized in that

Appl. No. 10/507,046

Amdt. Dated January 3, 2007

Reply to Office Action of October 3, 2006

it is produced recombinantly.

5. (Currently amended): The isolated ~~[[A]]~~ anti-anti-idiotypic antibody as claimed in claim 1 or claim 2, characterized in that it is produced by hybridoma cells as a monoclonal antibody.
6. (Currently amended): A ~~[[H]]~~ human hybridoma cell line which produces the monoclonal anti-anti-idiotypic antibody as claimed in claim 5.
7. (Currently amended): A ~~[[F]]~~ fragment of an anti-anti-idiotypic antibody as claimed in ~~any one of the claims~~ claim 1 ~~[[ to 5]]~~, characterized in that it has the binding specificity of the anti-anti-idiotypic antibody.
8. (Currently amended): The ~~[[F]]~~ fragment as claimed in claim 7, characterized in that it comprises a Fab or F(ab)<sub>2</sub> fragment of the anti-anti-idiotypic antibody optionally coupled to a human Fc part.
9. (Currently amended): A ~~[[P]]~~ pharmaceutical composition comprising an anti-anti-idiotypic antibody as claimed in ~~any one of the claims~~ claim 1 to 5 ~~or a fragment as claimed in claim 7 or claim 8~~.
10. (Currently amended): The ~~[[P]]~~ pharmaceutical composition as claimed in claim ~~[[8]]~~ 9, characterized in that it additionally contains common pharmaceutical carriers and adjuvants.
11. (Currently amended): The ~~[[P]]~~ pharmaceutical composition as claimed in claim 9 or claim 10 for the treatment and/or prophylaxis of CA1125-expressing tumours.

**Appl. No. 10/507,046**

**Amdt. Dated January 3, 2007**

**Reply to Office Action of October 3, 2006**

12. (Withdrawn): Use of an anti-anti-idiotypic antibody as claimed in any one of the claims 1 to 5 or a fragment as claimed in claim 7 or claim 8 for the treatment and/or prophylaxis of CA125-expressing tumours.
13. (New): A pharmaceutical composition comprising a fragment as claimed in claim 7.
14. (New): A pharmaceutical composition comprising a fragment as claimed in claim 8.